Pharmanovia Acquires CNS Portfolio From Sanofi
Pharmanovia announced on September 18 the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi. According to data captured in the LevinPro HC database, this transaction is the 75th Pharmaceutical acquisition of 2023. Sanofi is selling a portfolio of CNS brands, including Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren®, Castilium®, Gardenal®, Tercian® and Stemetil®. The brands span four therapy areas of ongoing unmet need associated with CNS disorders – psycholeptic, anxiolytic, anti-epileptic and anti-psychotic. Pharmanovia (formerly known as Atnahs Pharma UK Limited) is a... Read More »
Waud Capital Partners Launches PharmAlliance Holdings
Waud Capital Partners, a growth-oriented middle market private equity firm based in Chicago, announced on September 14 that it launched PharmAlliance Holdings, LLC. This was done in partnership with Mark Bouck, who will serve as Chief Executive Officer of the platform. PharmAlliance Holdings is a diversified pharmaceutical and life sciences services provider focused on discovery, development and commercialization solutions. Its services span across the drug life cycle for pharmaceutical, biotechnology, life sciences and medical device companies. In conjunction with its launch, PharmAlliance invested in BioBridges, a drug development consulting business serving... Read More »
Nestlé Divests Peanut Allergy Brand to Stallergenes Greer
Nestlé Health Science announced on September 5 its divestment of Palforzia, a children’s peanut allergy drug, to Stallergenes Greer International AG. According to data captured in the LevinPro HC database, this transaction represents the 77th Pharmaceuticals acquisition of 2023. Palforzia became the first drug approved by the FDA for peanut allergy in children in January 2020. At the time, it was projected that the drug could reach $1.28 billion in sales by 2024. Backed by B-FLEXION, Stallergenes Greer International AG is a global biopharmaceutical company. It is based in Baar, Switzerland and specializes in the diagnosis and treatment of respiratory allergies through... Read More »
VitalPoint Technologies Acquires Herban Healing
Houston-based VitalPoint Technologies, Inc. (VPT) announced on August 31 it acquired Herban Healing, LLC. The financial terms of the transaction were not disclosed. Herban Healing is a Texas-based biopharmaceutical company focused on healthcare products centered around CBD. Co-Founders Kyle Williams and Jennifer Gillelan established Herban Healing with the goal of addressing the opioid epidemic. Founded in 2019, the company operates two locations in Cypress, Texas and one in North Spring, Texas. VitalPoint Technologies was established to conduct research, develop solutions and provide education on alternative healthcare options. VPT is a tech-enabled innovative Healthcare... Read More »
LEO Pharma Acquires Timber Pharmaceuticals
LEO Pharma A/S announced on August 21 it acquired Timber Pharmaceuticals LLC, a biopharmaceutical company focused on developing and commercializing treatments for orphan dermatologic diseases. Timber Pharmaceuticals’ lead investigational product candidate, TMB-001, is a topical reformulation of the active ingredient, isotretinoin, which is aimed at treating congenital ichthyosis, a rare skin disease with significant unmet needs and no approved prescription therapies available. Founded in 1908, LEO Pharma A/S is owned by the LEO Foundation, one of Denmark’s largest commercial foundations. LEO Pharma is a specialty pharmaceutical company focused on dermatology, and markets products in more... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
